Enzolytics, Inc. (OTCMKTS:ENZC – Get Free Report) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totaling 972 shares, a growth of 365.1% from the April 30th total of 209 shares. Based on an average daily volume of 45,094,851 shares, the days-to-cover ratio is currently 0.0 days.
Enzolytics Price Performance
Shares of OTCMKTS:ENZC remained flat at $0.00 during midday trading on Friday. The company had a trading volume of 10,353,296 shares, compared to its average volume of 8,894,000. Enzolytics has a fifty-two week low of $0.00 and a fifty-two week high of $0.00.
Enzolytics Company Profile
Enzolytics, Inc is a clinical-stage biotechnology company focused on advancing immunotherapeutic treatments for infectious diseases. Its core platform employs proprietary peptide and monoclonal antibody technologies designed to target and neutralize viral pathogens. The company’s lead candidate, Investigator Therapeutic Vaccine-1 (ITV-1), is a 72-amino-acid peptide engineered to bind multiple HIV-1 strains and support immune response in affected individuals.
In addition to its HIV program, Enzolytics has leveraged its antibody discovery engine to develop broadly neutralizing monoclonal antibodies against coronaviruses, including SARS-CoV-2.
Featured Stories
- Five stocks we like better than Enzolytics
- Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem
- These 3 Software Stocks Are Buying Back Shares Hand Over Fist
- Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%
- MongoDB’s AI Advantage Is Starting to Show Up in Results
Receive News & Ratings for Enzolytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzolytics and related companies with MarketBeat.com's FREE daily email newsletter.
